Australia markets closed

Blue Water Vaccines Inc (J4T.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.1526-0.0006 (-0.39%)
As of 08:07AM CET. Market open.
Full screen
Previous close0.1532
Open0.1526
Bid0.1581 x N/A
Ask0.1680 x N/A
Day's range0.1526 - 0.1526
52-week range0.1371 - 1.6500
Volume0
Avg. volume2,029
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date09 Mar 2024 - 13 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

    CINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and patients in oncology, today announced the appointment of Ajit Singh, Ph.D. and Thomas Meier, Ph.D. to its Board of Directors. “We are thrilled to announce the addition of Dr. Singh and Dr. Meier to the Board of Directors of Onconetix,” stated Chair

  • GlobeNewswire

    Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

    CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategi

  • GlobeNewswire

    Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

    Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancerCINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the “Transaction”), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on